MRI pathway and TRUS-guided biopsy for detecting clinically significant prostate cancer

To determine the diagnostic accuracy of, and the concordance between, the MRI pathway and TRUS-guided biopsy approach for detecting clinically significant prostate cancer in men with a suspicion of prostate cancer, using template-guided biopsy as the reference standard.

To investigate what clinical and methodological sources of heterogeneity affect the accuracy of the tests, including type of population (initial biopsy or previous negative biopsy), type of prostate cancer (clinically significant or clinically insignificant), MRI scoring system, MRI suspicion score threshold for MRI-targeted biopsy, navigational approach of MRI-targeted biopsy, MRI lesion location, number of biopsy cores (or biopsy density) and core distribution in the reference standard.

This is a protocol.

Share/Save